Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Black Diamond Therapeutics, Inc. | exhibit312_q12021.htm |
| EX-31.1 - EX-31.1 - Black Diamond Therapeutics, Inc. | exhibit311_q12021.htm |
| 10-Q - 10-Q - Black Diamond Therapeutics, Inc. | bdtx-20210331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Chief Executive Officer, and Thomas Leggett, the Chief Financial Officer, of Black Diamond Therapeutics, Inc. (the “Company”), hereby certify, that, to their knowledge:
(1)the Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 7, 2021 | By: | /s/ David M. Epstein | ||||||||||||
David M. Epstein President, Chief Executive Officer and Director (Principal Executive Officer) | ||||||||||||||
| Date: May 7, 2021 | By: | /s/ Thomas Leggett | ||||||||||||
Thomas Leggett Chief Financial Officer (Principal Financial Officer) | ||||||||||||||